These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28494491)

  • 1. Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides.
    de Cogan F; Hill LJ; Lynch A; Morgan-Warren PJ; Lechner J; Berwick MR; Peacock AFA; Chen M; Scott RAH; Xu H; Logan A
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2578-2590. PubMed ID: 28494491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits.
    Giannos SA; Kraft ER; Luisi JD; Schmitz-Brown ME; Reffatto V; Merkley KH; Gupta PK
    Pharm Res; 2024 Jun; 41(6):1247-1256. PubMed ID: 38839719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of Cell-Penetrating Peptide anti-VEGF Formulations for the Treatment of Age-Related Macular Degeneration.
    Nikoi ND; Berwick M; Bryant JA; Riordan L; Slope L; Peacock AFA; de Cogan F
    Curr Eye Res; 2021 May; 46(5):751-757. PubMed ID: 33896277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Application of Cell-Penetrating Peptide Modified Anti-VEGF Drug Alleviated Choroidal Neovascularization in Mice.
    Hu W; Cai W; Wu Y; Ren C; Yu D; Li T; Shen T; Xu D; Yu J
    Int J Nanomedicine; 2024; 19():35-51. PubMed ID: 38187905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
    Lu F; Adelman RA
    Graefes Arch Clin Exp Ophthalmol; 2009 Feb; 247(2):171-7. PubMed ID: 18781316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
    Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
    Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
    Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
    Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Administration of Ranibizumab and Bevacizumab for Choroidal Neovascularization Secondary to Ocular Toxocariasis: A Case Report.
    Yoon DY; Woo SJ
    Ocul Immunol Inflamm; 2018; 26(4):639-641. PubMed ID: 27775459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor.
    Roy R; Saurabh K; Bansal A; Kumar A; Majumdar AK; Paul SS
    Indian J Ophthalmol; 2017 Apr; 65(4):295-300. PubMed ID: 28513493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System.
    Osswald CR; Guthrie MJ; Avila A; Valio JA; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2017 Sep; 42(9):1293-1301. PubMed ID: 28557571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
    You JY; Chung H; Kim HC
    Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration.
    Sun C; Zhang S; Xu N; Liu K; Wei F; Zhang X; Zhang J; Gao S; Yu Y; Ding X
    Int J Nanomedicine; 2024; 19():1887-1908. PubMed ID: 38414529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation.
    Rodrigues GA; Lutz D; Shen J; Yuan X; Shen H; Cunningham J; Rivers HM
    Pharm Res; 2018 Oct; 35(12):245. PubMed ID: 30374744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs.
    Tran J; Craven C; Wabner K; Schmit J; Matter B; Kompella U; Grossniklaus HE; Olsen TW
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3732-3740. PubMed ID: 28738417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
    Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on "Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5-Associated Liposomes": Topical Liposomal Bevacizumab Results in Negligible Retinal Concentrations.
    Urtti A
    Small; 2019 Apr; 15(15):e1805199. PubMed ID: 30977598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.